I think what we are "not seeing" is a clear path forward for how investors are supposed to make money on RVX. Until that path forward for BetOnMace2 is laid out in some detail new retail money, which sets current price (management has always seemed unclear on that concept), has no clue as to what their financial risk/reward is. Yes the science is very promising but will management make a good deal for shareholders' or will they make a bad one. Even the new Saudi money is only to keep the lights on until the go forward is figured out. Perhaps that will also fund the Covid trial, it sounds like there is a chance we could get lucky with that if management can get organized and get going.

Unfortunately with the big picture go forward we are not talking about good business management when we are talking RVX. This is the same group that for around 20 years has not been able to monetize anything they have talked about in the past, never been able to partner or license on other "promising compounds", never been able to make a licensing deal for cash without equity and due to chronically poor sp have been selling big investors equity at a rate of 5 to 10 cents on the dollar as compared to what management says the enterprise value of the company is. Not exactly the type of business execution that inspires retail investors to put their money into RVX.  I'm glad Don is now "having fun again", many RVX investors still aren't.  History has shown us that generally anyone who put money into RVX for the long term and not bought and sold the swings have been big investment losers, again not investment inspiration. 

I can only speak for myself but I definitely won't put any new money into RVX until I see that management has come to a deal where I can see clearly what the potential reward is on whatever further risk I am willing to take. Biotech always has inherent science risk but for me right now the bad management risk is way to big for any further investment. JMO